We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Topical cosmetic ingredient — not a dietary supplement
Kojic Acid is a topical cosmetic ingredient, not a supplement you take internally and not a drug. It is sold legally in skincare products to affect the appearance of skin (such as wrinkles). The evidence below comes mostly from small, often industry-funded studies of topical application, so treat the effect sizes cautiously. This page is for transparency and education, not a recommendation.
What the evidence says
Most Kojic Acid studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality meta-analyses and randomised trials published 1995–2023 with a typical study size of 50 participants.
Based on 7 studies · 1 meta-analysis · 3 RCTs · 435 total participants
Confidence
ModerateBy outcome
Kojic Acid has an evidence score of 6/10 — moderate evidence based on 7 indexed studies, including 1 meta-analysis. A topical skin-brightening active applied to the skin for hyperpigmentation and melasma — a cosmetic, not ingested. Kojic acid is a fungal-derived tyrosinase inhibitor (it chelates the copper at the enzyme's active site, slowing melanin production). It has genuine human RCT support for melasma and appears in a large 2023 meta-analysis with a statistically significant effect. The honest framing: the effect size is modest — the weakest of the major depigmenting agents in that meta-analysis — and most of the strong evidence is for kojic acid ADDED to hydroquinone/glycolic-acid bases rather than used alone. Contact sensitisation (allergy) is a well-documented downside of long-term use. These are cosmetic appearance outcomes, not health outcomes. Representative study: PMID 36566490.
The commonly studied dose of Kojic Acid is Topical cosmetic only. Kojic acid is typically used at roughly 1-2% in leave-on serums or creams (or as the more stable kojic acid dipalmitate), applied to areas of hyperpigmentation once or twice daily, often alongside other brighteners and daily sunscreen. There is no oral, injectable, or systemic dose — it is not ingested. This library does not provide an ingestion protocol.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Practical, evidence-based guides that cover Kojic Acid.
Explore: Best supplements for Skin, Hair & Beauty
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Kojic Acid (topical)
A topical skin-brightening active applied to the skin for hyperpigmentation and melasma — a cosmetic, not ingested. Kojic acid is a fungal-derived tyrosinase inhibitor (it chelates the copper at the enzyme's active site, slowing melanin production). It has genuine human RCT support for melasma and appears in a large 2023 meta-analysis with a statistically significant effect. The honest framing: the effect size is modest — the weakest of the major depigmenting agents in that meta-analysis — and most of the strong evidence is for kojic acid ADDED to hydroquinone/glycolic-acid bases rather than used alone. Contact sensitisation (allergy) is a well-documented downside of long-term use. These are cosmetic appearance outcomes, not health outcomes.
Genuine human RCT support for melasma and a confirmed tyrosinase-inhibition mechanism, included in a large 2023 meta-analysis with a statistically significant effect — but the effect size is the smallest among major depigmenting agents, the strongest evidence is for kojic acid combined with hydroquinone/glycolic acid rather than monotherapy, and contact sensitisation is a documented risk.
Kojic acid (5-hydroxy-2-(hydroxymethyl)-4-pyranone) is a metabolite produced by Aspergillus and Penicillium fungi, used as a topical skin-lightening active in cosmetics, typically around 1-2% (the more stable kojic acid dipalmitate is also used). This entry covers TOPICAL cosmetic use — it is not ingested.
Mechanistically, kojic acid inhibits tyrosinase, the rate-limiting enzyme of melanogenesis, by chelating the copper ions at its active site; a biochemical comparison found it about ten times more potent than arbutin or hydroquinone in a purified-enzyme assay, though far weaker than 4-n-butylresorcinol and only modestly active in artificial-skin melanin assays.
The clinical evidence is real but modest and largely combination-based. A split-face RCT (Lim, 1999) showed that adding 2% kojic acid to a 10% glycolic acid + 2% hydroquinone gel further improved melasma (60% vs 47.5% achieving clearance).
A four-arm RCT (Deo et al., 2013) found kojic acid combined with hydroquinone was the most effective regimen, with kojic acid monotherapy weaker.
A large 2023 systematic review and meta-analysis (Chang et al.; 45 efficacy studies, 2359 patients) found kojic acid produced a statistically significant MASI reduction — but the smallest effect size among the major agents (standardised mean difference -0.9, versus -1.3 to -1.6 for hydroquinone, cysteamine, tranexamic acid, and azelaic acid) — while having a low skin-irritation rate (5.3%).
The honest counter-evidence: a head-to-head trial (Azzam et al., 2009) found topical hydroquinone + kojic acid underperformed chemical peels for melasma; a pilot (Hermanns et al., 2002) found a 1% kojic acid combination inefficacious on solar lentigines; and crucially, contact allergy is a recognised hazard — a patch-test series (Nakagawa et al., 1995) judged kojic acid to have 'high sensitizing potential,' with users developing facial dermatitis 1-12 months after starting kojic-acid products.
None of this is a health claim: kojic acid is a lawful cosmetic whose documented benefit is a modest improvement in the appearance of hyperpigmentation, best realised in combination with other actives and tempered by a real sensitisation risk.
It is listed under Beauty & Appearance so it is discoverable, but is sandboxed out of ingestible-supplement stacks and the schedule optimizer; it carries a cosmetic badge and a topical-only disclaimer.
Kojic acid chelates the copper ions at the active site of tyrosinase, the rate-limiting enzyme of melanin synthesis, slowing pigment production. In a purified-enzyme assay it was ~10x more potent than arbutin or hydroquinone, but only modestly active in artificial-skin melanin models — consistent with its real-but-modest clinical effect.
Kojic acid has antioxidant activity that may contribute to its effect on UV- and inflammation-driven pigmentation, complementing direct tyrosinase inhibition.
Topical cosmetic only. Kojic acid is typically used at roughly 1-2% in leave-on serums or creams (or as the more stable kojic acid dipalmitate), applied to areas of hyperpigmentation once or twice daily, often alongside other brighteners and daily sunscreen. There is no oral, injectable, or systemic dose — it is not ingested. This library does not provide an ingestion protocol.
| Form | Type |
|---|---|
| 🧴Leave-on topical serum or cream (≈1-2% kojic acid, or kojic acid dipalmitate) | Recommended |
| 💊Combination brightening formulas containing kojic acid | Alternative |
There is no oral or injectable cosmetic form. Kojic acid is a skincare active applied to the skin surface.
Minimum: 8 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Applied to pigmented areas once or twice daily. As a leave-on cosmetic there is no ingestion or meal-timing consideration; daily sunscreen is essential for any pigment goal.
The documented benefit is a modest improvement in the APPEARANCE of hyperpigmentation. Kojic acid is a topical cosmetic ingredient, not an ingested supplement, and it does not treat any disease.
Human trials show a statistically significant reduction in melasma, especially when kojic acid is combined with hydroquinone or glycolic acid. The standalone effect is smaller.
In a large meta-analysis kojic acid had the smallest effect of the major depigmenting agents, and it underperformed chemical peels head-to-head. Expect a supporting-actor role, not a standalone fix.
Kojic acid is considered to have high sensitising potential; some users develop facial contact dermatitis weeks to months after starting it. Patch-test and watch for delayed irritation.
Topical kojic acid has limited safety data in pregnancy and lactation; discuss with a clinician, and consider better-studied alternatives like azelaic acid.
Higher sensitisation risk — patch-test and monitor for delayed contact dermatitis.
Manage expectations — kojic acid is a modest, usually adjunct brightener; hydroquinone, azelaic acid, or clinician-guided combinations have stronger evidence, and daily sunscreen is essential.
Often combined with other brighteners/exfoliants, which can increase irritation; introduce gradually. This is a tolerability/formulation consideration, not a systemic drug interaction — it is not ingested.
Tip: Patch-test first; sensitisation can appear weeks to months in. Discontinue if facial dermatitis develops.
Tip: Reduce frequency or concentration; buffer with moisturizer.
Timing is flexible for Kojic Acid — consistent daily use matters more than the time of day. Kojic acid is a leave-on topical with no meal-timing relationship; pairing with daily sunscreen matters more, since UV drives the pigmentation it targets.
Kojic Acid is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are contact dermatitis / allergic sensitisation, local irritation, redness, or stinging. Use caution if any of these apply to you: For topical (skin) use only — not for ingestion, not for injection; Known allergy or sensitivity to kojic acid; Application to broken, irritated, or compromised skin until healed.